Marijuana Reclassification Raises More Questions Than Answers for Business

The Celebration Comes With Caveats

The cannabis industry is celebrating the biggest federal policy shift since prohibition began — but behind the champagne toasts and stock rallies, executives, lawyers, and regulators are grappling with a cascade of unanswered questions that could define the industry's trajectory for years to come.

The Department of Justice's April 23 order reclassifying state-licensed medical marijuana from Schedule I to Schedule III is unquestionably historic. It provides immediate tax relief, eases research barriers, and signals federal tolerance that seemed impossible just a few years ago. But as Marketplace reported within hours of the announcement, the reclassification raises as many questions as it answers — perhaps more.

The 280E Question Is Not as Simple as It Looks

The most cited benefit of Schedule III classification is the elimination of IRS Code Section 280E, which has prevented cannabis businesses from deducting ordinary business expenses. The tax burden under 280E has been staggering — some operators report effective tax rates of 70 percent or higher. Schedule III removes this burden for covered businesses.

But the relief applies only to state-licensed medical marijuana operations. Recreational cannabis businesses, which account for the majority of the $47 billion U.S. market, remain in limbo until the Phase Two hearing evaluates broader rescheduling. This creates a two-tier system where medical operators gain a massive competitive advantage over recreational-only businesses.

For companies that hold both medical and recreational licenses, the accounting becomes extraordinarily complex. How do you allocate shared costs — rent, utilities, labor — between a tax-advantaged medical operation and a still-280E-burdened recreational operation housed in the same facility? The IRS has not issued guidance, and tax professionals are already warning that aggressive interpretations could invite audits.

Banking Remains Unresolved

The rescheduling was supposed to fix cannabis banking. It has not — at least not yet. The core problem is that banks are regulated by federal agencies that have historically treated cannabis deposits as proceeds of drug trafficking. While Schedule III classification removes some of the legal basis for that position, it does not eliminate it entirely.

Schedule III substances are still controlled substances. Testosterone and ketamine — both Schedule III — are legal only through licensed pharmacies and medical providers. Cannabis dispensaries, even medical ones, do not fit neatly into the pharmaceutical distribution framework that banks understand and are comfortable with.

Major national banks are taking a wait-and-see approach. Their compliance departments are reviewing the new classification but have not rushed to open cannabis accounts. Credit unions and state-chartered banks that already serve cannabis clients may expand their services, but the fundamental problem — that cannabis remains federally controlled — persists.

The SAFE Banking Act, which would explicitly protect financial institutions that serve state-legal cannabis businesses, remains stalled in Congress. Without it, Schedule III alone may not be enough to open the floodgates of traditional banking.

Interstate Commerce Remains Illegal

One of the most significant limitations of Schedule III classification is that it does not create a framework for interstate cannabis commerce. Cannabis grown in Oregon cannot legally be shipped to a dispensary in New York, regardless of both states having legal markets. Each state operates as an isolated market, which drives up costs and limits competition.

Schedule III status does not change this because the reclassification operates within the existing Controlled Substances Act framework, which requires federal licensing for the manufacture and distribution of controlled substances across state lines. No such licensing framework exists for cannabis.

This means the patchwork of 40 separate state markets continues. Operators in oversaturated markets like Oregon and Colorado cannot sell surplus production to undersupplied markets in the East. Consumers in high-price markets continue paying more than necessary. And the industry's chronic overproduction problems in some states remain unsolvable without interstate commerce.

The FDA Question Looms

Schedule III classification brings cannabis under closer FDA oversight — a development that the industry has not fully reckoned with. Schedule III substances typically require FDA approval for marketing and sale, a process that involves clinical trials, manufacturing standards, and labeling requirements that most cannabis businesses are not prepared to meet.

The DOJ's order applies specifically to state-licensed medical marijuana, effectively acknowledging state regulatory frameworks as a proxy for the FDA approval process. But this arrangement is legally novel and could face court challenges. How the FDA interprets its authority over Schedule III cannabis — and whether it chooses to exercise that authority aggressively — remains one of the largest unknowns facing the industry.

If the FDA decides to enforce pharmaceutical-grade manufacturing standards on cannabis, the compliance costs would be prohibitive for most small and medium operators. Only the largest multi-state operators have the resources to meet FDA requirements, which could accelerate the industry's already rapid consolidation.

Recreational Markets Wait and Watch

The Phase Two hearing beginning June 29 will determine whether Schedule III classification extends to all cannabis, including recreational programs. The hearing is scheduled to conclude by July 15, but the resulting decision could take months or years to implement.

In the meantime, recreational cannabis operators face a strategic dilemma. Do they invest in expanding operations based on the expectation that broader rescheduling is coming? Or do they hold back, preserving cash in case the Phase Two process stalls or produces a less favorable outcome?

This uncertainty is particularly acute for companies making acquisition and merger decisions. Cannabis M&A activity has been driven partly by the expectation of federal reform — but the current half-measure creates a risk that deals priced for full rescheduling may not deliver the expected returns.

Stock Market Whiplash

Cannabis stocks surged immediately after the rescheduling announcement, with the MSOS ETF and individual operators posting double-digit gains. But history suggests caution. The cannabis sector has experienced repeated cycles of policy-driven rallies followed by sell-offs when the anticipated reforms prove slower or more limited than expected.

The current situation has elements of both bull and bear cases. The 280E relief for medical operators is immediate and quantifiable, supporting higher valuations. But the unanswered questions about banking, interstate commerce, recreational markets, and FDA oversight introduce risks that the market has not fully priced in.

Investors who bought into cannabis stocks after previous reform signals — the initial Obama-era Cole Memo, the first rescheduling discussions in 2024, Trump's executive order — have been burned by the gap between headlines and implementation.

The Competitive Landscape Shifts

Perhaps the most underappreciated consequence of the rescheduling is how it changes competitive dynamics within the industry. Medical operators with Schedule III status now have significantly lower tax burdens than their recreational counterparts. In states with dual-license systems, this creates an incentive to shift sales toward the medical channel — potentially at the expense of the recreational market that generates most state tax revenue.

State regulators are watching this closely. If medical sales surge while recreational sales decline, the tax revenue implications could be significant. Some states may respond by adjusting their regulatory frameworks to ensure that rescheduling does not inadvertently undermine their recreational markets.

What Industry Leaders Should Do Now

The wisest course for cannabis businesses is to pursue immediate opportunities while preparing for continued uncertainty. Medical operators should work with their accountants to begin claiming 280E deductions immediately — the tax savings are real and substantial.

All operators should strengthen their compliance infrastructure. If broader rescheduling brings increased federal oversight, companies with robust compliance programs will be best positioned to navigate the new regulatory environment.

Businesses should resist the temptation to make major capital commitments based on the assumption that Phase Two will proceed smoothly. The history of cannabis reform is littered with expected milestones that arrived late, arrived differently than expected, or did not arrive at all.

The Bigger Picture

The DOJ's reclassification is a genuine milestone — the most significant change in federal cannabis policy in nearly a century. But it is a milestone on a long road, not a destination. The questions it raises about banking, interstate commerce, FDA authority, recreational markets, and competitive dynamics will take years to resolve fully.

For an industry accustomed to operating in legal ambiguity, this is familiar territory. Cannabis businesses have always navigated uncertainty — between state and federal law, between investor expectations and regulatory reality, between the promise of a legal market and the persistence of prohibition-era constraints.

The reclassification adds new dimensions to that uncertainty even as it resolves old ones. Navigating the transition successfully will require the same combination of adaptability, patience, and strategic thinking that has defined the industry's most successful operators.

For consumers tracking how individual operators are responding, you can find a dispensary near you on Budpedia — many state-licensed retailers are already updating menus, prices, and tax disclosures in response to the Schedule III shift.